{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:50:22Z","timestamp":1782287422983,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Knowledge regarding lorazepam use during breastfeeding is limited and so are quantitative data on lorazepam transfer into human milk. Lorazepam transfer to human milk was characterized in a single case and pharmacovigilance databases were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A clinical lactation study was conducted in a breastfeeding mother who used lorazepam as needed for anxiety symptoms (single 1\u00a0mg oral dose, 6.5 months postpartum). Serial human milk (n = 6) and maternal plasma (n = 2) samples were collected over 24\u00a0h. Concentration-time data were used to calculate plasma and milk AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      (linear trapezoidal interpolation), milk-to-plasma (M\/P) ratios, daily and relative infant dose (DID, RID). Because of the\n                      <jats:italic>a priori<\/jats:italic>\n                      pragmatic design (limited sampling), published plasma concentration\u2013time profiles following oral dose were searched, digitized and dose-normalized to derive a plasma AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      . Pharmacovigilance data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database and Eudravigilance were analyzed for \u201c\n                      <jats:italic>lorazepam related exposure via human milk<\/jats:italic>\n                      \u201d.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Milk concentrations ranged from 0.65 to 2.10\u00a0ng\/mL, with highest levels at 1.5\u00a0h. The milk AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      was 25.36\u00a0ng*h\/mL. Literature-derived plasma AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      was 158.94\u00a0ng*h\/mL resulting in an AUC-based M\/P ratio of 0.16, calculated DID was 218\u00a0ng\/kg\/day. Assuming milk intakes of 150 and 200\u00a0mL\/kg\/day, estimated DID values were 176.26 and 235.02\u00a0ng\/kg\/day respectively, corresponding to RID values of 1.35% and 1.80%, increasing up to 3.85% upper-bound estimates. The RID\n                      <jats:sub>therapeutic<\/jats:sub>\n                      was 0.44%, increasing to 0.81% in upper-bound estimates. FAERS identified 25 reports of lorazepam exposure via human milk, Eudravigilance one, with mainly central nervous system (CNS) related symptoms. In all these cases, lorazepam was part of CNS polypharmacy, while no lorazepam monotherapy related events were retrieved.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest low infant exposure following occasional single, low-dose lorazepam use during breastfeeding. While interpretation should remain cautious given the single-case design, the single low dose, limited plasma sampling, and milk concentrations below the validated lower limit of quantification, the available pharmacokinetic data suggest low estimated infant exposure following occasional low-dose lorazepam use. Pharmacovigilance findings provided contextual information but should not be interpreted as confirmatory evidence of safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1877310","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:45:18Z","timestamp":1782287118000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lorazepam during breastfeeding: a pharmacokinetic case report and exploratory pharmacovigilance assessment \u2013 a contribution from the ConcePTION project"],"prefix":"10.3389","volume":"17","author":[{"given":"Ghazaleh","family":"Shitreh","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martje","family":"Van Neste","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences","place":["Leuven, Belgium"]},{"name":"Woman and Child, Department of Development and Regeneration","place":["Leuven, Belgium"]},{"name":"Teratology Information Service, Netherlands Pharmacovigilance Centre Lareb","place":["\u2018sHertogenbosch, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ceulemans","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences","place":["Leuven, Belgium"]},{"name":"Research Foundation Flanders (FWO)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen","place":["Groningen, Netherlands"]},{"name":"Department of Pediatrics, Beatrix Children\u2019s Hospital, University Medical Center Groningen, University of Groningen","place":["Groningen, Netherlands"]},{"name":"Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen","place":["Groningen, Netherlands"]},{"name":"Pharmacometrics Expertise Center of the Northern Netherlands, University Medical Center Groningen, University of Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fclya","family":"Tezel-Yal\u00e7\u0131n","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Hacettepe University","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Huan","family":"Olsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Copenhagen University Hospital \u2013 Bispebjerg and Frederiksberg","place":["Copenhagen, Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gade","sequence":"additional","affiliation":[{"name":"Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences","place":["Leuven, Belgium"]},{"name":"BioNotus CommV","place":["Niel, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen","place":["Groningen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Annaert","sequence":"additional","affiliation":[{"name":"Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences","place":["Leuven, Belgium"]},{"name":"BioNotus CommV","place":["Niel, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Smits","sequence":"additional","affiliation":[{"name":"Woman and Child, Department of Development and Regeneration","place":["Leuven, Belgium"]},{"name":"Neonatal Intensive Care Unit, University Hospitals Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Allegaert","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences","place":["Leuven, Belgium"]},{"name":"Woman and Child, Department of Development and Regeneration","place":["Leuven, Belgium"]},{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100251","DOI":"10.1016\/j.focus.2024.100251","article-title":"Concurrent prescription fills of opioids and benzodiazepines among postpartum women during COVID-19","volume":"3","author":"Abraham","year":"2024","journal-title":"AJPM Focus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00737-024-01488-4","article-title":"Increases in benzodiazepine prescribing for postpartum anxiety during COVID-19","volume":"28","author":"Adams","year":"2025","journal-title":"Arch. Womens Ment. Health"},{"key":"B3","unstructured":"The cost of not breastfeeding tool\n          \n          \n          2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/bfm.2022.0008","article-title":"Treating insomnia during breastfeeding","volume":"17","author":"Anderson","year":"2022","journal-title":"Breastfeed. Med."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5863\/jppt-26-00104","article-title":"Assessing the safety of medications during lactation","author":"Anderson","year":"2025","journal-title":"J. Pediatr. Pharmacol. Ther. Online"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jad.2020.03.014","article-title":"Prevalence of benzodiazepines and benzodiazepine-related drugs exposure before, during and after pregnancy: a systematic review and meta-analysis","volume":"269","author":"Bais","year":"2020","journal-title":"J. Affect Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/089033402237904","article-title":"Studying drugs in human milk: time to unify the approach","volume":"18","author":"Begg","year":"2002","journal-title":"J. Hum. Lact."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1395982","DOI":"10.3389\/fphar.2024.1395982","article-title":"Adverse drug reactions in neonates: a brief analysis of the FDA adverse event reporting system","volume":"15","author":"Byskov","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(25)39467-X","article-title":"Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding","volume":"267","author":"Chaudhary","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B11","volume-title":"Lorazepam","year":"2024"},{"key":"B12","article-title":"ICH guideline M10 on bioanalytical method validation and study sample analysis","volume":"44","year":"2022","journal-title":"ICH Harmon. Guidel."},{"key":"B13","volume-title":"Lorazepam 1 mg Tablets: Summary of Product Characteristics (Smpc)","year":"2026"},{"key":"B14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cpt1976203329","article-title":"Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam","volume":"20","author":"Greenblatt","year":"1976","journal-title":"Clin. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/jps.2600680119","article-title":"Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans","volume":"68","author":"Greenblatt","year":"1979","journal-title":"J. Pharm. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/jps.2600710227","article-title":"Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam","volume":"71","author":"Greenblatt","year":"1982","journal-title":"J. Pharm. Sci."},{"key":"B17","volume-title":"Hale\u2019s Medications and Mothers\u2019 Milk: A Manual of Lactational Pharmacology","author":"Hale","year":"2021"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/bcp.70063","article-title":"EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding","volume":"91","author":"Heerfordt","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B18","article-title":"Lorazepam (systemic) drug monograph","volume-title":"IBM Watson Health","year":"2026"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1176\/appi.ps.53.1.39","article-title":"Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant","volume":"53","author":"Iqbal","year":"2002","journal-title":"Psychiatr. Serv."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1002\/jps.22093","article-title":"Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure","volume":"99","author":"Kamal","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2165\/00003495-198223050-00002","article-title":"Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations","volume":"23","author":"Kanto","year":"1982","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jpeds.2012.03.003","article-title":"Neonatal benzodiazepines exposure during breastfeeding","volume":"161","author":"Kelly","year":"2012","journal-title":"J. Pediatr."},{"key":"B23","volume-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2026"},{"key":"B24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/anae.70128","article-title":"Guidelines for anaesthesia and sedation for patients who are breastfeeding: guidelines from the association of anaesthetists","volume":"81","author":"Mitchell","year":"2026","journal-title":"Anaesthesia"},{"key":"B25","volume-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"B26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1089\/bfm.2020.0259","article-title":"Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose","volume":"16","author":"Nishimura","year":"2021","journal-title":"Breastfeed. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jpba.2005.07.021","article-title":"Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples","volume":"40","author":"Papini","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B28","volume-title":"PatchSA Paediatric Palliative Care Formulary","year":"2026"},{"key":"B29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(15)01044-2","article-title":"Why invest, and what it will take to improve breastfeeding practices?","volume":"387","author":"Rollins","year":"2016","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s44294-025-00064-0","article-title":"Clinical lactation studies. Acting on key recommendations over the last decade","volume":"3","author":"Rowland Yeo","year":"2025","journal-title":"NPJ Womens Health"},{"key":"B31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/clpt.1986.90","article-title":"Sedative effects and impaired learning and recall after single oral doses of lorazepam","volume":"39","author":"Shader","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"key":"B32","unstructured":"Using benzodiazepines during breastfeeding\n          \n          \n          2024"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/bja\/57.10.1042-a","article-title":"Excretion of lorazepam into breast milk","volume":"57","author":"Summerfield","year":"1985","journal-title":"Br. J. Anaesth."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3390\/ph17121654","article-title":"Drug safety during breastfeeding: a comparative analysis of FDA adverse event reports and LactMed\u00ae","volume":"17","author":"Tezel Yal\u00e7\u0131n","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B35","volume-title":"Ativan\u00ae (Lorazepam) Tablets","year":"2016"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e002385","DOI":"10.1136\/bmjpo-2023-002385","article-title":"Determining the exposure of maternal medicines through breastfeeding: the UmbrelLACT study protocol-a contribution from the ConcePTION project","volume":"8","author":"Van Neste","year":"2024","journal-title":"BMJ Paediatr. Open"},{"key":"B37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(15)01024-7","article-title":"Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect","volume":"387","author":"Victora","year":"2016","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1877310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:45:32Z","timestamp":1782287132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1877310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":38,"alternative-id":["10.3389\/fphar.2026.1877310"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1877310","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1877310"}}